Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 18, 2011, Pages 5239-5243

  Huang, Wenwei ^a   Huang, Ruili ^a   Attene Ramos, Matias S ^a   Sakamuru, Srilatha ^a   Englund, Erika E ^a   Inglese, James ^a   Austin, Christopher P ^a   Xia, Menghang ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Hypoxia inducible factor 1 ; Parallel synthesis; Quinazolin 4 ones

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN INHIBITOR; QUINAZOLIN 4 ONE ANALOG; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ONE POT SYNTHESIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UPREGULATION;

CHEMISTRY TECHNIQUES, SYNTHETIC; HIGH-THROUGHPUT SCREENING ASSAYS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR STRUCTURE; QUINAZOLINONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80051923846     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.043     Document Type: Article

References (29)

1. A. Weidemann, and R.S. Johnson Cell Death Differ. 15 2008 621
2. N. Yewalkar, V. Deore, A. Padgaonkar, S. Manohar, B. Sahu, P. Kumar, A. Jalota-Badhwar, K. Joshi, S. Sharma, and S. Kumar Bioorg. Med. Chem. Lett. 20 2010 6426
3. S.-Y. Park, W.-J. Jang, E.-Y. Yi, J.-Y. Jang, Y. Jung, J.-W. Jeong, and Y.-J. Kim J. Pineal Res. 48 2010 178
4. K. Shimizu, M. Maruyama, Y. Yasui, H. Minegishi, H.S. Ban, and H. Nakamura Bioorg. Med. Chem. Lett. 20 2010 1453
5. T. Narita, S. Yin, C.F. Gelin, C.S. Moreno, M. Yepes, K.C. Nicolaou, and E.G. Van Meir Clin. Cancer Res. 15 2009 6128
6. A.C. Kasper, E.J. Moon, X. Hu, Y. Park, C.M. Wooten, H. Kim, W. Yang, M.W. Dewhirst, and J. Hong Bioorg. Med. Chem. Lett. 19 2009 3783
7. M.-S. Won, N. Im, S. Park, S.K. Boovanahalli, Y. Jin, X. Jin, K.-S. Chung, M. Kang, K. Lee, S.-K. Park, H.M. Kim, B.M. Kwon, J.J. Lee, and K. Lee Biochem. Biophys. Res. Commun. 385 2009 16
8. M. Uno, H.S. Ban, and H. Nakamura Bioorg. Med. Chem. Lett. 19 2009 3166
9. J.A. Diaz-Gonzalez, J. Russell, A. Rouzaut, I. Gil-Bazo, and L. Montuenga Cancer Biol. Ther. 4 2005 1055
10. H. Harada, and M. Hiraoka Curr. Signal Transduction Ther. 5 2010 188
11. S.R. Mooring, and B.H. Wang Sci. China:Chem. 2011 24
12. Y. Li, and D. Ye Curr. Cancer Drug Tar. 10 2010 782
13. G. Semenza Drug Discovery Today 2007 19
14. R.J. DeBerardinis, J.J. Lum, G. Hatzivassiliou, and C.B. Thompson Cell Metab. 2008 11
15. X.-H. Wang, B.E. Cavell, S.S. Alwi, and G. Packham Biochem. Pharmacol. 78 2009 261
16. P. Garcia-Maceira, and J. Mateo Oncogene 28 2009 313
17. S.H. Li, D.H. Shin, Y.-S. Chun, M.K. Lee, M.-S. Kim, and J.-W. Park Mol. Cancer Ther. 7 2008 3729
18. L.M. Greenberger, I.D. Horak, D. Filpula, P. Sapra, M. Westergaard, H.F. Frydenlund, C. Albaek, H. Schroder, and H. Orum Mol. Cancer Ther. 7 2008 3598
19. H.S. Ban, U. Yoshikazu, and H. Nakamura Expert Opin. Ther. Patents 2011 131
20. M. Xia, K. Bi, R. Huang, M.-H. Cho, S. Sakamuru, S.C. Miller, H. Li, Y. Sun, J. Printen, C.P. Austin, and J. Inglese Mol. Cancer 8 2009 117
21. Becklin, R. R.; Chepanoske, C. L.; Pelter, J. M.; Qi, L.; Robbins, P. B.; Sahasrabudhe, S. R.; Selliah, R.; Simmons, K.; Stockwell, B. R.; Venkat, R. G.; Von Rechenberg, M.; Zhen, E. PCT Int. Appl., WO2006081331, 2006.
22. + 365.1983, found 365.1982.
23. J.F. Liu, J.Y. Lee, A.M. Dalton, G. Bi, L.B. Yu, C.M. Baldino, E. McElory, and E. Brown Tetrahedron Lett. 2005 1241
24. TM B/G FRET substrate (Invitrogen, Carlsbad, CA) mixture was added into the plates, the assay plates were incubated at room temperature for 2.5 h, and the fluorescence intensity (405 nm excitation, and 460 and 530 nm emissions) was measured by an Envision plate reader (Perkin Elmer, Shelton CT).
25. 6 HRE-bla ME-180 cells per well were cultured in a 6-well plate. After 6 h, the cells were treated for 17 h with DMSO in a normal atmosphere (negative control) and 1% oxygen (positive control), or with 1 or 10 μM solutions of 16 or 18 in DMSO at 1% oxygen. After the treatment, the cells were lysed in lysis buffer (Invitrogen) containing 1% of protease inhibitor (Sigma) for 10 min on ice. After the samples were centrifuged for 10 min at 14000 rpm and 4 °C, supernatants were collected and subjected to SDS-PAGE analysis on a 10% Tris-Glycine gel (Invitrogen). Same amount of protein (25 μg) from each sample was loaded into the gel. Proteins were transferred to a PVDF membrane (Invitrogen) and the membrane was blotted with primary antibodies against HIF-1α at a 1:250 dilution (Santa Cruz Biotechnologies, Santa Cruz, CA) or β-Actin at 1:5000 dilution (Sigma) as a loading control. HRP conjugated secondary antibody (1:1000 dilution; anti-goat anti-rabbit or anti-mouse, Santa Cruz, CA) was used together with the Western Blot Luminol reagent kit (Santa Cruz Biotechnology, CA) to develop the membrane that was read with the ChemiDoc XRS system (Bio-Rad, Hercules, CA).
26. N. Yagoda, M. von Rechenberg, E. Zaganjor, A.J. Bauer, W.S. Yang, A.J. Fridman, I. Smukste, J.M. Peltier, J.J. Boniface, R. Smith, S.L. Lessnick, S. Sahasrabudhe, and B.R. Stockwell Nature 447 2007 864
27. W.S. Yang, and B.R. Stockwell Chem. Biol. 2008 234
28. J. Lim, E. Lee, H. You, J.W. Lee, J. Park, and J. Chun Oncogene 2004 9427
29. R. Blum, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, and Y. Kloog Cancer Res. 2005 999